Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1999-12-03
2002-06-25
McGarry, Sean (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024300, C536S024310, C435S320100, C435S325000
Reexamination Certificate
active
06410238
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates generally to cancer diagnosis and therapy, and more specifically, to cancers associated with the Myc oncoprotein Myc is a transcription factor and key cell growth regulator that is frequently deregulated in human malignancy, notably Burkitt's and T cell lymphomas, where myc genes suffer chromosomal translocation. In colon and lung carcinomas, myc genes are amplified (M. D. Cole,
Ann Rev. Genet
., 20:361-384 (1986)). Paradoxically, under certain conditions myc can induce apoptosis, a regulated cell suicide process (D. S. Askew et at,
Oncogene
, 6;1915-1922 (1991); G. I. Evanetal,
Cell
, 69:119-128 (1992)). However, loss or suppression of apoptosis is an important step in the malignant conversion of human tumors containing deregulated myc oncogenes, including, prominently, prostate carcinoma (T. G. Strohmeyer et al,
J. Urol
., 151:1479-1497(1994)).
There remains a need in the art for compositions and methods of regulating a deregulated Myc protein and of exploiting and/or diagnosing its apoptotic potential.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides mammalian Bin1 nucleic acid sequences and peptides encoded thereby. Currently preferred are alternative splice exons 12A, 12B, 12C and 12D, which are brain-specific splice forms of Bin1 found in malignant cells. The most preferred alternative splice exon is currently Exon 12A
In yet another aspect, the present invention provides a vector comprising a mammalian nucleic acid sequence encoding a Bin1 protein and a host cell transformed by such a vector. Alternatively, this vector may be used in gene therapy applications.
In still another aspect, the invention provides an oligonucleotide probe comprising a nucleic acid sequence as defined herein. Also provided is an antibody raised against a Bin1 protein or peptide thereof.
In yet a further aspect, the present invention provides a diagnostic reagent for breast, prostate, or liver cancer, or deficient Bin1 production, comprising an oligonucleotide probe or an antibody of the invention.
Further provided is a therapeutic reagent comprising a polypeptide, anti-idiotype antibody, or gene therapy vector of the invention.
Still another aspect of the invention provides a method of treating breast, prostate, or liver cancer by administering a therapeutic reagent of the invention.
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof
REFERENCES:
patent: 4419446 (1983-12-01), Howley et al.
patent: 5605830 (1997-02-01), Prendergast et al.
patent: 5723581 (1998-03-01), Prendergast et al.
patent: WO 91/18088 (1991-11-01), None
patent: WO 96/31625 (1996-10-01), None
patent: WO 96/34627 (1996-11-01), None
patent: WO 98/55151 (1998-12-01), None
M. Cole, “The myc Oncogene: Its Role in Transformation and Differentiation”,Ann. Rev. Genet., 20:361-384 (Dec. 1986).
D. Askew et al., “Constitutive c-myc Expression in an Il-3-dependent Myeloid Cell Line Suppresses Cell Cycle Arrest and Accelerates Apoptosis”,Oncogene, 6:1915-1922 (Oct. 1991).
G. Evan et al., “Induction of Apoptosis in Fibroblasts by c-myc Protein”,Cell, 69:119-128 (Apr. 3, 1992).
T. Strohmeyer et al., “Review Article—Proto-Oncogenes and Tumor Suppressor Genes in Human Urological Malignancies”,J. Urol., 151:1479-1497 (Jun. 1994).
G. Mark et al., “Humanization of Monoclonal Antibodies”, Chapter 4,The Handbook of Experimental Pharmacology, vol. 113, The Pharmacology of Monoclonal Antibodies, Springer-Verlag (Jun. 1994).
S. Fields et al., “A Novel Genetic System to Detect Protein-Protein Interactions”,Nature, 340:245-246 (Jul. 20, 1989).
D. Negorev et al., “The Bin1 Gene Localizes to Human Chromosome 2q14 by PCR Analysis of Somatic Cell Hybrids and Fluorescence in Situ Hybridization”,Genomics, 33:329-331 (Apr. 1996).
Databases EMBL/genebank/DDBJ on MPSRCH, Accession No. Z24792, Auffray et al., (Jul. 30, 1993).
Database Genexpress on MPSRCH, Accession No. Z28487, Auffray et al., (Dec. 9, 1993).
Databases EMBL/Genebank/DDBj on MPSRCH, Accession No. F00405, Auffray et al. (Mar. 7, 1995).
Database IMAGE Consortium, LLNL on MPSRCH, Accession No. R34418, Hillier et al. (May 2, 1995).
Databases EMBL/Genebank/DDBJ on MPSRCH, Accession No. Z24784, Auffray et al. (Jul. 30, 1993) [Auffray IV].
The Washington-Merck EST Project on MPSRCH, Accession No. R18250, Hillier et al., (Apr. 14, 1995) [Hillier II].
D. Sakamuro et al., “The Polyproline Region of P53 is Required to Activate Apoptosis But Not Growth Arrest”,Oncogene, 15:887-898 (Aug. 21, 1997).
D. Sheiness et al., “Identification of Nucleotide Sequences which may Encode the Oncogenic Capacity of Avian Retrovirus MC29”,J. Virol.., 28(2):600-610 (Nov. 1978).
M-J. Gething et al. “Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene”,Nature, 293:620-625 (Oct. 22, 1981).
R. Kaufman et al., “Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster Ovary Cells”,Mol. Cell. Biol., 5(7):1750-1759 (Jul. 1985).
M. Kay et al., “In Vivo Hepatic Gene Therapy: Complete Albeit Transient Correction of Factor IX Deficiency in Hemophilia B Dogs”,Proc. Natl. Acad. Sci. USA, 91:2353-5357 (Mar. 1994).
S. Ishibashi et al., “Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice and Its Reversal by Adenovirus-mediated Gene Delivery”,J. Clin. Invest., 92:883-893 (Aug. 1993).
W. Huse et al., “Research Article—Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”,Science, 246:1275-1281 (Dec. 8, 1989).
A. Vojtek et al., “Mammalian Ras Interacts Directly with the Serine/Threon Kinase Raf”,Cell, 74:205-214 (Jul. 16, 1993).
G. Prendergast et al., “A New Bind for MYC”,Trends in Genet., 8(3):91-97 (Mar. 1992 [Prendergast I].
A. Rustgi et al., “Amino-terminal Domains of c-myc and N-myc Proteins Mediate Binding to the Retinoblastoma Gene Product”,Nature, 352:541-544 (Aug. 1991).
G. Prendergrast et al., “Biphasic Effect of Max on Myc Cotransformation Activity and Dependence on Amino- and Carboxy-terminal Max Functions”,Genes Dev., 6:2429-2439 (Dec. 1992) [Prendergast II].
A. Kelekar et al., “Immortalization by c-myc, H-ras, and E1a Oncogenes Induces Differential Cellular Gene Expression and Growth Factor Responses”,Mol. Cell. Biol., 7(11):3899-3907 (Nov. 1987).
C. Shih et al., “Isolation of a Transforming Sequence from a Human Bladder Carcinoma Cell Line”,Cell, 29:161-169 (May 1982).
E. Douglas et al., “A Specific Chromosomal Abnormality in Rhabdomaysarcoma”,Cytogenet. Cell Genet., 45:148-155 (May 15, 1987).
G. Prendergast et al., “Postranscriptional Regualation of Cellular Gene Expression by the c-myc Oncogene”,Mol. Cell Biol., 9(1):124-134 (Jan. 1989) [Prendergast III].
F. Bauer et al., “Alteration of a Yeast SH3 Protein Leads to Conditional Viability with Defects in Cytoskeletal and Budding Patterns”,Mol. Cell. Biol., 13(8):5070-5084 (Aug. 1993).
B. Lichte et al., “Amphiphysin, a Novel Protein Associated with Synaptic Vesicles”,EMBO J., 11(7):25221-2530 (Jul. 1992).
C. David et al., Autoimmunity in Still-man Syndrome with Breast Cancer is Targeted to the C-Terminal Region of Human Amphiphysin, a Protein Similar to the Yeast Proteins, Rvs167 and Tvs161FEBS Letters, 351:73-79 (Jul. 1994).
D. Miller et al., “An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes”,Genetic Engineering, 8:277-298 (1986).
R. Wechsler-Reya, et al., “Structural Analysis of the Human BIN1 Gene: Evidence for Tissue-Specific Transcriptional Regulation and Alternate RNA Splicing”,J. Biol. Chem., 272(50):31453-31458 (Dec. 12, 1997).
R. Wechsler-Reya et al., “The Putative Tumor Suppressor BIN1 is Short-Lived Nuclear Phosphoprotein, The Localization of Which is Altered in Malignant Cells”,Cancer Research, 57:3258-3268 (Aug. 1, 1997).
R. Wechsler-Reya et al., “A Role for The Putative Tumor Suppressor BIN1 in Muscle Cell Differentiation”,Mo
Prendergast George C.
Sakamuro Daitoku
Howson and Howson
McGarry Sean
The Wistar Institute of Anatomy and Biology
LandOfFree
Box-dependent Myc-interacting protein (Bin1) compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Box-dependent Myc-interacting protein (Bin1) compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Box-dependent Myc-interacting protein (Bin1) compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2958779